|
|
| (84 intermediate revisions by 6 users not shown) |
| Line 1: |
Line 1: |
| | | {{Details0|Metoprolol succinate (tablet)}} |
| __NOTOC__
| | {{Details0|Metoprolol tartrate (injection)}} |
| {{CMG}} | | {{Details0|Metoprolol tartrate (tablet)}} |
| | |
| '''''For patient information about Metoprolol, click [[Metoprolol (patient information)|here]].'''''
| |
| | |
| {{SB}} Lopressor<sup>®</sup>, Toprol XL<sup>®</sup>
| |
| {{Metoprolol}} | |
| | |
| ==Overview==
| |
| | |
| '''Metoprolol''' is a selective [[beta blocker|β<sub>1</sub> receptor blocker]] used in treatment of several diseases of the cardiovascular system, especially [[hypertension]]. The active substance metoprolol is employed either as ''metoprolol [[succinic acid|succinate]]'' or as ''metoprolol [[tartrate]]'' (where 100 mg metoprolol tartrate corresponds to 95 mg metoprolol succinate). The tartrate is an immediate-release and the succinate is an extended-release [[Pharmaceutical formulation|formulation]].<ref>{{cite journal | author = Cupp M | title = Alternatives for Metoprolol Succinate | journal = Pharmacist's Letter / Prescriber's Letter | year = 2009 | volume = 25 | issue = 250302 | url = http://www.ncbop.org/PDF/MetoprololShortageMarch2009.pdf | format = pdf | accessdate = 2012-07-06 }}</ref>
| |
| | |
| ==Category==
| |
| | |
| Beta-blockers, Antimigraine drugs
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ====LOPRESSOR (metoprolol tartrate) tablet====
| |
| | |
| ''' [[Metoprolol indications and usage|Indications and Usage]]'''
| |
| '''| [[Metoprolol dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Metoprolol contraindications|Contraindications]]'''
| |
| '''| [[Metoprolol warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Metoprolol adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Metoprolol drug interactions|Drug Interactions]]'''
| |
| '''| [[Metoprolol use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Metoprolol overdosage|Overdosage]]'''
| |
| '''| [[Metoprolol description|Description]]'''
| |
| '''| [[Metoprolol clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Metoprolol nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Metoprolol clinical studies|Clinical Studies]]'''
| |
| '''| [[Metoprolol how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Metoprolol patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Metoprolol labels and packages|Labels and Packages]]'''
| |
| | |
| {| style="border: 3px solid #696969;"
| |
| | style="background: #000000; border: 0px; padding: 0 5px; width: 800px;" |
| |
| | |
| | |
| <center>
| |
| <font color="#F8F8FF">'''WARNING'''</font>
| |
| </center>
| |
| | |
| <center>
| |
| <font color="#F8F8FF" size="1">''See full prescribing information for complete boxed warning.''</font>
| |
| </center>
| |
| | |
| | |
| <b><font color="#F8F8FF">
| |
| Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered Lopressor, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, Lopressor administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue Lopressor therapy abruptly even in patients treated only for hypertension.
| |
| </font></b>
| |
| | |
| | |
| |}
| |
| | |
| ====TOPROL XL (metoprolol succinate) tablet, extended release====
| |
| | |
| ''' [[Metoprolol succinate indications and usage|Indications and Usage]]'''
| |
| '''| [[Metoprolol succinate dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Metoprolol succinate contraindications|Contraindications]]'''
| |
| '''| [[Metoprolol succinate warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Metoprolol succinate adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Metoprolol succinate drug interactions|Drug Interactions]]'''
| |
| '''| [[Metoprolol succinate use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Metoprolol succinate overdosage|Overdosage]]'''
| |
| '''| [[Metoprolol succinate description|Description]]'''
| |
| '''| [[Metoprolol succinate clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Metoprolol succinate clinical studies|Clinical Studies]]'''
| |
| '''| [[Metoprolol succinate how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Metoprolol succinate patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Metoprolol succinate labels and packages|Labels and Packages]]'''
| |
| | |
| {| style="border: 3px solid #696969;"
| |
| | style="background: #000000; border: 0px; padding: 0 5px; width: 800px;" |
| |
| | |
| | |
| <center>
| |
| <font color="#F8F8FF">'''WARNING'''</font>
| |
| </center>
| |
| | |
| <center>
| |
| <font color="#F8F8FF" size="1">''See full prescribing information for complete boxed warning.''</font>
| |
| </center>
| |
| | |
| | |
| <b><font color="#F8F8FF">
| |
| Following abrupt cessation of therapy with beta-blocking agents, exacerbations of angina pectoris and myocardial infarction have occurred. Warn patients against interruption or discontinuation of therapy without the physician’s advice.
| |
| </font></b>
| |
| | |
| | |
| |}
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Beta blockers]]
| |